Analysis and explanation of telisotuzumab-EMRELIS injection course and clinical usage plan

Telisotuzumab (trade name EMRELIS) is a monoclonal antibody drug conjugate targeting the c-Met receptor (ADC), mainly used to treat non-small cell lung cancer (NSCLC) with high expression of c-Met. This drug specifically binds to c-Met receptors on the surface of tumor cells and delivers cytotoxic drugs directly to cancer cells, thereby achieving precise killing while reducing damage to normal tissues. Clinical trials have shown that it has certain efficacy in patients with relapsed or refractory c-Met high expression.

Clinical use regimens for EMRELIS are generally administered by intravenous infusion. The standard recommended dose is administered as an intravenous infusion once every three weeks. The length of the treatment course is generally determined by the patient's tolerance, tumor response, and adverse reactions. Doctors will dynamically adjust the medication plan based on imaging examinations and laboratory indicators. Blood routine, liver and kidney function, and potential allergic reactions need to be closely monitored during treatment to ensure safety.

In terms of treatment schedule, a comprehensive assessment is usually conducted before the first dose of injection, including confirmation of tumorc-Met expression levels, basic liver and kidney function tests, and previous drug use history. During the initial administration, medical staff will observe the patient for infusion-related reactions, such as fever, chills, or blood pressure fluctuations. If mild to moderate adverse reactions occur, treatment can be continued by extending the infusion time or symptomatic treatment; if severe reactions occur, the medication needs to be suspended and subsequent dosages adjusted.

Generally speaking, the treatment course design of territuzumab (EMRELIS) is centered on patient individualization, emphasizing both efficacy monitoring and safety management. Through intravenous administration at fixed intervals, regular imaging follow-up and laboratory monitoring, doctors can ensure the efficacy of the drug while minimizing the risk of adverse reactions. Patients should strictly follow the doctor's instructions during use and do not change the dosage or stop the medication early to achieve the best therapeutic effect.

Reference materials:https://www.drugs.com/